The shares of the biopharmaceutical company jumped up to 2 percent after the company announced a collaboration to expand Insulin Aspart access in the United States.
Price movement
With a market capitalization of Rs 40,292.14 crore, the shares of Biocon Ltd were trading at Rs 335.55 per share, increasing around 0.74 percent as compared to the previous closing price of Rs 333.10 apiece.
Reason for rise
The shares of Biocon Ltd have seen bullish movement after announcing a collaboration with Civica, Inc to expand Insulin Aspart access in the United States. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., which will manufacture the drug product in Virginia.
Civica will commercialize it in the U.S. after development and trials. The agreement involves no technology transfer, ensuring continued control over Biocon’s proprietary processes.
Financial Performance
Analyzing a company’s financial performance, revenue slashed by 3 percent from Rs 3,954 crore in Q3FY24 to Rs 3,821 crore in Q3FY25, during the same time frame, the company’s net profit decreased significantly by 89 percent from Rs 753 crore to Rs 81 crore.
Also: PSU railway stock jumps 4% after receiving ₹156 Cr order from South Western Railways
Market Outlook
The company anticipates multiple biosimilar launches, with five expected by FY27. It is gaining market share in the U.S. and Europe, maintaining leadership in key products. Ongoing cost improvement programs aim to boost profitability and recover lost business in the Generics segment.
Future Outlook
Management expects growth in H2 FY25 and FY26, with mid-teens expansion in Generics driven by new launches and capacity increases. R&D investment will remain 6%-9% of revenue to support long-term portfolio growth, ensuring sustained innovation and competitiveness across all business segments.
Company Profile
Biocon Limited focuses on treating diabetes, cancer, and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologic, and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule active pharmaceutical ingredients (APIs).
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
